Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. INOVIO (NASDAQ ...

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Inovio Pharmaceuticals, Inc.’s INO share price has surged by 10.67%, which has investors questioning if this is right time to sell.

Shares of Inovio Pharmaceuticals Inc. INO advanced 1.90% to $1.61 Friday, on what proved to be an all-around positive trading ...

Inovio Pharmaceuticals (INO) has been beaten down lately with too much selling pressure. While the stock has lost 11.4% over ...

Inovio Pharmaceuticals Inc. closed 89.14% below its 52-week high of $13.44, which the company reached on May 16th.

Desjardins analyst A. Leon anticipates that the company will earn $0.01 per share for the quarter. Desjardins also issued ...